Chronic multiple sclerosis (MS) is diagnosed with a range of unpredictable symptoms and periods, such as impaired body coordination and balance, fatigue, visual disturbances, sensory changes, sensitivity to heat, cognitive and emotional disorders and bladder and bowel dysfunction (
1).
There are about 2.5 million people with MS worldwide (
2). The prevalence of MS is reported as 5 - 30 per 100,000 people in Iran (
3). Iran was previously among the regions with a low prevalence of MS; however, over the last decade, the number of patients with MS increased and the prevalence of MS appears to have increased to a moderate or even high level in Iran (
4).
There are no cures for MS, and treatments are therefore based on the regulation of the immune system with interferon-beta, controlling the symptoms and non-pharmacological interventions (
5). About 84% of patients with MS have lower urinary tract dysfunction (
6). The most frequent bladder dysfunction in MS is an overactive bladder, which causes urinary incontinence (
7). Urinary incontinence affects the social, psychological, occupational, familial and physical aspects of the patients' lives and limits their ability to enjoy daily activities, social relations, traveling and personal relationships and imposes heavy costs on the patients and the healthcare systems (
8,
9). Psychological manifestations of MS include anxiety, stress, depression, cognitive disorders, irritability and anger, with the most prevalent ones being anxiety, stress and depression (
10). About 48% of patients experience anxiety, stress and depression in the first year of diagnosis with MS, and these symptoms tend to highly affect the patients’ quality of life (
11). In addition to being a disease by itself, urinary incontinence exacerbates depression, anxiety, stress, insomnia and other psycho-social problems in patients with MS and negatively affects the quality of life as a common complication (
8). Patients with MS, who are mostly in their youth, are embarrassed by problems such as urinary incontinence and find their self-confidence faltered (
12).
Urinary incontinence is treated by methods such as surgery, hormone therapy, pharmacotherapy, electrical stimulation, pelvic floor muscle exercises and mechanical devices. The pharmacotherapy method uses anticholinergic (antimuscarinic) drugs, with numerous side effects, such as constipation, dizziness, urinary retention and skin rash (
13-
15). In addition to posing the risk of urinary incontinence relapse, surgical methods require the appropriate facilities and a highly competent surgeon impose heavy costs and may also cause other complications (
16). Pelvic floor muscle exercises are alternative solutions that play a major role to prevent and treat urinary incontinence (
17). Given the many complications that pharmacotherapy causes, it appears reasonable to opt for non-pharmacological methods of reducing anxiety, stress and depression in patients with MS (
18).
Complications such as fatigue and bladder and bowel problems can be managed and improved through proper instructions and treatments (
19). Through the improvement of complications, the patient can perform a higher-quality self-care and reduce his psychological problems (
20). Given the high prevalence of urinary incontinence in patients with MS, and given that pelvic floor muscle exercises are non-pharmacological, non-invasive and cost-effective method to control urinary disorders in the patients that can be easily instructed by the medical personnel, including nurses and given the lack of published research on the effect of pelvic floor muscle training on urinary incontinence, stress, anxiety and depression in MS patients in Iran.